Agnes Lee Email & Phone Number

San Diego, Ca, Us

Agoura Hills, California, Us

Responsible for leading investor relations and communications functions as a member of the Senior Leadership Team. ACELYRIN, INC (Nasdaq: SLRN) is a Los Angeles area-based late stage clinical biopharma company - with additional operations in the San Francisco Bay Area - focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN has two programs in late-stage clinical development. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R advancing into Phase 2b/3 development for the treatment of thyroid eye disease. Izokibep is a next generation inhibitor of IL-17A in Phase 2b/3 development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis.

Goleta, California, Us

Responsible for building a global investor relations program to promote the company to security analysts, institutional and individual shareholders and financial media. Also responsible for building the companies strategic planning capabilities, refining the company’s strategy and communicating Inogen’s strategy externally and internally. DEIBA Inclusion Ambassador and member of Inogen’s DEIBA TaskforceInogen (Nasdaq: INGN), is a medical technology company offering respiratory products for use in the homecare setting. Inogen primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-oxygen therapy to patients suffering from chronic respiratory conditions. For more information, please visit www.inogen.com

Burlington, Massachusetts, Us

Responsible for building a global investor relations, investor communications and ESG program to promote the company to security analysts, institutional and individual shareholders and media.Butterfly Network Inc’s (NYSE: BFLY) mission is to democratize healthcare by enabling universal access to superior medical imaging, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-On-Chip TM technology, Butterfly Network is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ and next generation Butterfly iQ+ have received CE Mark and FDA clearance, and are being sold in hospitals and clinics around the globe.

South San Francisco, California, Us

Responsible for the creation, development and execution of global investor relations and communications programs and strategies to promote the company to security analysts, institutional and individual shareholders and media.Finance leader with execution and communications impact on the company’s capital structure for equity and debt transactions.Improving life. It’s what drives us each day. At Fluidigm (NASDAQ: FLDM), we empower our customers to reveal meaningful insights in health and disease, identify actionable markers to inform life decisions and accelerate the development of more effective therapies.We focus on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy. Harnessing proprietary CyTOF® and microfluidics capabilities, we provide an unprecedented view into health and disease through our unique combination of innovative mass cytometry, tissue imaging and genomics solutions.Researchers depend on our systems to uncover important disease pathways, find valuable new molecular biomarkers and deeply profile important cell populations down to single cell resolution. As a trusted partner of leading academic, government, pharmaceutical, biotechnology and plant and animal research laboratories worldwide, we strive to increase the quality of life for all. For more information, visit us at Fluidigm.com

San Diego, Ca, Us

Responsible for the creation, development and execution of global investor relations and corporate communications programs and strategies to promote the company to external stakeholders including: security analysts, institutional and individual shareholders, global media, industry analysts and thought leaders. Completed executive leadership program including a strategy project to shape the company’s strategy in Japan. Led workstream for change management and communication. ResMed Inc is traded on both the NYSE and ASX with a market capitalization of $14 Billion.ResMed Inc. (NYSE: RMD, ASX: RMD) changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

San Diego, Ca, Us

Responsible for the creation, development and execution of global investor relations programs and strategies to promote the company to security analysts, institutional investors and individual shareholders. ResMed Inc is traded on both the NYSE and ASX with a market capitalization of $14 Billion.ResMed Inc. (NYSE: RMD, ASX: RMD) changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Waltham, Ma, Us

Responsible for the development and execution of global investor relations programs and strategies to promote the company to security analysts, institutional investors and individual shareholders. Serve as primary contact with 24 Wall Street analysts who currently provide research coverage for Life Technologies, as well as all current and potential shareholders. Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. For more information on how we are making a difference, please visit our website: www.lifetechnologies.comLife Technologies current market cap is approximately $13 billion.

Waltham, Ma, Us

Provided financial and executive business partnering to manage the P&Ls for the company's fast-paced Next Generation Sequencing and Bioinformatics businesses. Responsibilities included $100 million in R&D expenses; key partner for product commercialization and strategic budgeting. Managed a team of 4 professionals.

Waltham, Ma, Us

Supported the qPCR and CE businesses. Partnered with the business management teams to manage business P&Ls. Responsible for financial planning, analysis, reporting, forecasting for revenue, margins, operating expenses, headcount, capital expenditures, product commercialization, R&D project analysis. Managed a team of 3 professionals.

Involved in all financial aspects of the business within a start-up environment. Created and managed P&L & cash flow monthly forecasting and annual budgeting process. Responsible for strategic planning, financial management of a joint venture relationship with a large Pharma partner, launching an S&OP process; financial partnering with the Chief Business Officer to manage a portfolio of diagnostic assays including HIV, HCV, Cystic Fibrosis and transplant diagnostics, tracking all royalty revenue and expense contracts; developing a financial process for tracking and forecasting clinical sample expenses and contracts that were used in discovery research, replication and utility studies.

Responsible for originating, structuring, executing media & telecommunications debt transactions. Spearheaded due diligence of a media company in Hong Kong and China; acted as U.S. liaison to support Asia (non-Japan) new business origination and transaction execution efforts; coordinated undergraduate recruiting and managed staff of seven professionals.

Charlotte, Nc, Us

Originated and executed high yield and investment debt transactionsfrom marketing/acquisition phase to closing. Evaluated acquisition-financing proposals from private equity clients, executed and sold four private placement debt transactions. Responsible for financial modeling, transaction structuring, due diligence, writing internal credit and offering memorandums, developing and participating in rating agency and roadshow presentations. Completed investment banking rotation program.

Master Of Business Administration (Mba), Finance & Marketing

Bachelor Of Arts (Ba), International Economics And Affairs